# PhillipCapital

# Axis Bank (AXSBIN)

# Macro headwinds pose a challenge

# INDIA | FINANCIALS | Quarterly Update

# Top takeaways from Q3FY20

- ✓ NII of Rs 64.5bn (+15% yoy) was driven by strong domestic loan growth (+25%) and higher NIM of 3.57% (+7bps qoq). Other income at Rs 37.8bn (-5% yoy) was lower than our estimate on lower fee and commission income. Opex were higher and Provisions were inline. Over all PBT at Rs 22.7bn was marginally below our estimate
- Slippages increased sequentially to Rs 62.1bn (2Q20: 49.8bn) including Rs 10.9 bn slippage from investment book (HFC). Gross slippages from Corporate were Rs 38.9 bn (81% from disclosed BB & below).
- ✓ GNPA at 5.0% (-3bps gog) while NNPA at 2.09% (+10bps). PCR declined 1% gog to 78%.
- ✓ Loan growth grew by +16% yoy, driven by retail loans (+25% yoy) and Corporate loans (+9.0% yoy). SME loans were relatively flat yoy.

# Management comments / concall takeaways

- **BB** and **Below book:** NFB exposure in BB and below book increased by Rs 14 bn qoq to Rs 36.7bn largely due to telecom a/c. In FB exposure to BB and below book gross addition were around Rs 12-13bn and net addition was around Rs 9bn. BB and below Investment book declined by Rs9.0bn due to slippage of one large HFC account
- Opex: Higher opex was on account of increase in investment in branches and one time front loading of Rs 1.2bn of expense. Expense in 4Q20 will be impacted by PSLs & expenditure towards branch expansion. Cost to asset to consolidate in near term before coming down to 2% in medium terms
- NIM: Increase in NIM was due to higher spread impact of capital raise partly offset by
  interest reversal. Going forward NIM is likely to be impacted by new LCR calculations as
  run-off rate of certain category of deposits have been changed by RBI which could lead
  to higher buffer thus impacting NIMs. For FY20 NIM is expected to be higher than FY19
- **Credit Cost:** Credit cost in 4Q20 will be driven by few large recoveries and increase in coverage as bank would want to use some of the proceeds to ramp up coverage

**Outlook and valuation:** Performance on various guided vectors like 1. Risk Normalisation 2. Business Optimization and 3. Operating efficiency has been tepid given macro headwinds. However we draw comfort from the declining pool of stress asset, elevated coverage and visible NPA resolution. We believe that the near term challenges are priced in and expect improvement in above mentioned vectors in medium term. We expect ROA of 1.3%/1.6% in FY21/22 and ROE to rebound to 12%/15%. At CMP, the stock trades at 2.3x/2x FY21/FY22 ABVPS of Rs 315/361. Maintain Buy with a TP of Rs 800 valuing at 2.5x FY21 ABVPS of Rs 315.

## 22 Jan 2020

# **BUY (Maintain)**

CMP RS 710 / TARGET RS 800 (+13%)

SEDI CATEGORY: LARGE CAP	
COMPANY DATA	
O/S SHARES (MN) :	2820
MARKET CAP (RSBN):	2024
MARKET CAP (USDBN):	28.5
52 - WK HI/LO (RS) :	828 / 623
LIQUIDITY 3M (USDMN):	90.2
PAR VALUE (RS):	2

#### SHARE HOLDING PATTERN, %

	Dec 19	Sep 19	Jun 19
PROMOTERS:	16.1	16.6	18.1
FII / NRI :	50.5	52.5	48.4
FI / MF :	21.0	20.4	17.9
NON PRO:	7.7	7.6	8.2
PUBLIC & OTHERS :	4.8	4.8	7.4

#### **KEY FINANCIALS**

Rs mn	FY20E	FY21E	FY22E
Pre-prov ROE (%)	30.0	26.2	28.3
Pre-prov ROA (%)	3.0	2.8	3.0
Net Profit	47	107	153
% growth	1.4	126.6	42.8
EPS (Rs)	16.8	37.8	53.7
BVPS (Rs)	277.1	314.6	360.8
ROE (%)	6.2	11.7	14.9
P/E (x)	42.3	18.8	13.2
Adj P/BV (x)	2.6	2.3	2.0

#### CHANGE IN ESTIMATES

	Revised	Est	% Rev	ision
Rs mn	FY20E	FY21E	FY20E	FY21E
Revenue	247.3	284.9	-0.9	-1.3
EBITDA	229.8	239.7	1.9	-2.0
Core PAT	47.4	107.4	-14.7	-5.9
EPS (Rs)	16.8	37.8	-14.9	-6.0

Manish Agarwalla, Research Analyst Sujal Kumar, Research Analyst

(Rs bn)	Q3FY20	Q3FY19	yoy %	Q2FY20	qoq %	vs. expect. %	Comments
Net interest income	64.5	56.0	15.2	61.0	5.8	1.9	Driven by 18% growth in domestic loan and higher NIM
NIM (%)	3.6	3.5	10bps	3.5	7bps	4bps	NIM improved 7bps qoq
Advances	5501.4	4751.0	15.8	5215.9	5.5	1.6	Growth driven by 26%/9% in retail/Corporate, SME was flat yoy
Corporate advances	2585.8	2427.1	6.5	2483.7	4.1		Domestic corporate 18% yoy & overseas -32% yoy
Retail advances	2915.5	2324.0	25.5	2732.2	6.7		
Deposit	5916.8	5140.9	15.1	5839.6	1.3		Term deposit grew 25% yoy(Retail Term: 37%) and CASA grew by 3% yoy
CASA	2437.5	2355.5	3.5	2400.5	1.5		Growth aided by 9% and -7% growth in savings and current respectively
CASA %	41%	46%	(5bps)	41%	bps		
Core fee	28.0	26.2	7.0	26.5	5.6		Retail fee income grew 20%, comprising 67% of total fee income
Trading gain	5.2	3.8	35.9	8.1	-36.3		
Operating exp	45.0	40.8	10.2	40.5	11.1	5.0	Employee exp. increased 13.5% yoy, other opex increased 8.8% yoy
C/I (%)	46.2	44.2	202bps	44.0	221bps		
Provision	34.7	30.5	13.6	35.2	-1.3	-1.8	Specific provision Rs29.6bn
PAT	17.6	16.8	4.5	-1.1	-1667.6	-2.2	
Slippage	62.1	49.8	24.7	37.5	65.9		Corporate Slippage 38.9bn, 81% from BB and below book
GNPA	5.0	5.8	(75bps)	5.0	(3bps)		PCR at 78%
NNPA	2.1	2.4	(27bps)	2.0	10bps		
Tier 1 Capital %	15.5	13.1	247bps	15.0	51bps		



Result update					
(Rs Bn)	Q3FY20	Q3FY19	yoy growth	Q2FY20	qoq growth
Interest earned	157	141	11.2	154	1.8
Interest expended	93	85	8.6	93	-0.9
Net interest income	65	56	15.2	61	5.8
Net interest margins	3.6	3.5	0.10	3.5	0.07
Non-interest income	38	40	-5.4	39	-2.8
Total Income	102	96	6.6	100	2.4
Total operating expenses	45	41	10.2	40	11.1
Payroll costs	14	12	13.5	13	7.1
Others	31	29	8.8	28	13.0
Pre-provision Profit	57	55	3.9	60	-3.5
Provisions & Contingencies	35	31	13.6	35	-1.3
% Operating income	60.4	55.3	5.2	59.1	1.3
PBT	23	25	-8.0	24	-6.6
Provision for Taxes	5	8	-34.8	25	-79.8
% of PBT	22.7	32.0	-9.3	104.6	-81.9
Net Profit	18	17	4.5	-1	NA
Equity	6	5	9.7	6	0.0
EPS, Rs	31.2	32.7	-4.7	-2.0	NA
Advances	5,501	4,751	15.8	5,216	5.5
Deposits	5,917	5,141	15.1	5,840	1.3
Advances / Deposits (%)	93.0	92.4	0.6	89.3	3.7
Gross NPAs	301	309	-2.5	291	3.4
Gross NPAs (%)	5.00	5.75	-0.75	5.03	0.0
Net NPAs	122	122	-0.6	111	9.2
Net NPAs (%)	2.09	2.36	-0.27	1.99	0.10
CAR - Tier I	15.5	13.1	2.5	15.0	0.5
CAR - Tier II	3.2	3.3	-0.2	3.2	0.0
CAR – Total	18.7	16.4	2.3	18.2	0.5

Source: Company, PhillipCapital India Research

Particulars, Rs bn	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20E	Q3FY20E
opening BB and below	104	89	76	75	75	63
less: slippage from BB and below pool	10	18	10	12	16	21
Less: Repayment and upgrades	6	0	1	10	7	3
Add: Fresh addition to BB and below pool	0	6	9	22	11	12
(A) Closing BB & below rated exposure	89	76	75	75	63	51
(B) Non Fund based exposure to BB & Below plus NPA	56	54	53	53	47	62
Loan				31	29	26
Investment				20	18	10
non fund based exposure				30	30	30
(C) Additional disclosure (excluding overlaps and NPAs)				81	77	66
Gross total stress book (A+B+C)	145	130	128	209	187	179
Less: Outstanding provision	0	6	19	24	26	26
Net total stress book	145	124	109	185	161	153
Gross customer asset	5191	5366	5663	5601	5780	6015
% of gross customer asset	2.8	2.3	1.9	3.3	2.8	2.5

 $Source: Company, Phillip Capital\ India\ Research$ 

E = Estimated



# **Financials**

Y/E Mar, Rs mn	FY19	FY20	FY21e	FY22e
Interest on Loans	413	483	566	667
Interest on Investments	113	111	113	128
Others	23	28	29	31
Total Interest Earned	550	622	708	826
Total Interest Expended	333	375	423	486
Net Interest Income	217	247	285	340
Total non-interest income	131	154	146	164
Total Income	348	401	431	504
Personnel Expenses	47	53	58	66
Other Expenses	111	119	132	147
Total Op expenses	158	171	191	212
Net Inc (Loss) before prov	190	230	240	291
Provision & cont.	120	138	96	87
Net Inc (Loss) before tax	70	92	143	205
Provision for Income Tax	23	44	36	51
Net Profit	47	47	107	153

# **Balance Sheet**

Y/E Mar, Rs mn	FY19	FY20	FY21e	FY22e
Assets				
Cash & Bal with RBI	672	546	600	660
Loans, Adv & Int accrued	4948	5708	6636	7697
Investments	1807	1651	1860	2092
Fixed Assets (Net)	40	42	44	46
Other assets	542	623	717	803
Total Assets	8,010	8,571	9,857	11,299
Liabilities				
Share capital	5	6	6	6
Reserves and Surplus	662	862	956	1089
Hybrid Capital	44	48	52	56
Debt	267	307	347	387
Borrowing	1217	791	919	1099
Total Deposits	5517	6187	7118	8105
Other liab incld prov	299	370	460	558
Total Liabilities	8,010	8,571	9,857	11,299


Source: Company, PhillipCapital India Research Estimates

# **Valuation Ratios**

	FY19	FY20	FY21e	FY22e
Earnings and Valuation Ratios				
Pre-provision Operating RoAE (%)	29.2	30.0	26.2	28.3
RoAE (%)	7.2	6.2	11.7	14.9
Pre-provision Operating ROA (%)	2.5	2.8	2.6	2.8
RoAB (%)	0.68	0.62	1.26	1.57
EPS (Rs.)	18.2	16.8	37.8	53.7
Dividend per share (Rs.)	1.0	2.0	4.0	6.0
Book Value (Rs.)	259.4	306.9	338.4	383.2
Adj BV (Rs.)	228.7	277.1	314.6	360.8
Revenue Analysis				
Interest income on IBA (%)	7.9	8.1	8.3	8.5
Interest cost on IBL (%)	5.1	5.2	5.4	5.4
NIM on IBA / AWF (%)	3.1	3.2	3.4	3.5
Core fee Inc / AWF (%)	1.5	1.5	1.5	1.5
Portfolio gains / Total Inc (%)	2.9	6.9	2.9	3.1
Op.Exp / TI (%)	46.8	45.7	45.6	43.5
Op.Exp / AWF (%)	2.3	2.2	2.2	2.2
Employee exps / Op exps (%)	30.0	30.7	30.6	30.8
Tax / Pre-tax earnings (%)	32.9	48.2	25.0	25.0
Asset Quality				
GNPAs / Gr Adv (%)	5.3	4.7	4.0	3.3
NNPAs / Net Adv (%)	2.1	1.9	1.3	1.1
Growth Ratio				
Loans (%)	12.5	15.4	16.2	16.0
Investments (%)	13.5	(8.7)	12.7	12.4
Deposits (%)	20.8	12.1	15.1	13.9
Networth (%)	5.1	30.1	10.8	13.8
Net Int Income (%)	16.6	13.9	15.2	19.3
Non-fund based income (%)	30.0	5.2	4.4	11.5
Non-Int Exp (%)	13.2	8.3	11.4	11.3
Profit Before Tax (%)	5,636.7	31.3	56.4	42.8
Net profit (%)	1,596.4	1.4	126.6	42.8
Asset / Liability Profile				
Avg CASA/ Deposits (%)	48.3	42.6	40.0	37.9
Avg Adv / Avg Dep (%)	86.3	85.9	88.2	90.3
Avg Invst / Avg Dep (%)	33.7	29.5	26.4	26.0
Incr Adv / Deposits (%)	58.1	113.5	99.5	107.6
Avg Cash / Avg Dep (%)	11.0	10.4	8.6	8.3
Capital Adequacy Ratio:	15.8	18.9	18.6	18.6
Tier I (%)	12.5	15.3	15.0	15.0
CET1 (%)	11.3	13.9	13.6	13.7
NNPAs to Equity (%)	16.9	13.9	10.0	8.4



# **Stock Price, Price Target and Rating History**



# Rating Methodology

We rate stock on absolute return basis. Our target price for the stocks has an investment horizon of one year. We have different threshold for large market capitalisation stock and Mid/small market capitalisation stock. The categorisation of stock based on market capitalisation is as per the SEBI requirement.

# Large cap stocks

Rating	Criteria	Definition
BUY	>= +10%	Target price is equal to or more than 10% of current market price
NEUTRAL	-10% > to < +10%	Target price is less than +10% but more than -10%
SELL	<= -10%	Target price is less than or equal to -10%.

#### Mid cap and Small cap stocks

Rating	Criteria	Definition
BUY	>= +15%	Target price is equal to or more than 15% of current market price
NEUTRAL	-15% > to < +15%	Target price is less than +15% but more than -15%
SELL	<= -15%	Target price is less than or equal to -15%.

# **Disclosures and Disclaimers**

PhillipCapital (India) Pvt. Ltd. has three independent equity research groups: Institutional Equities, Institutional Equity Derivatives, and Private Client Group. This report has been prepared by Institutional Equities Group. The views and opinions expressed in this document may, may not match, or may be contrary at times with the views, estimates, rating, and target price of the other equity research groups of PhillipCapital (India) Pvt. Ltd.

This report is issued by PhillipCapital (India) Pvt. Ltd., which is regulated by the SEBI. PhillipCapital (India) Pvt. Ltd. is a subsidiary of Phillip (Mauritius) Pvt. Ltd. References to "PCIPL" in this report shall mean PhillipCapital (India) Pvt. Ltd unless otherwise stated. This report is prepared and distributed by PCIPL for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by PCIPL to be valid when published. The report also contains information provided to PCIPL by third parties. The source of such information will usually be disclosed in the report. Whilst PCIPL has taken all reasonable steps to ensure that this information is correct, PCIPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and PCIPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

This report does not regard the specific investment objectives, financial situation, and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realised. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the



#### **AXIS BANK QUARTERLY UPDATE**

securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which PCIL believe is reliable. PhillipCapital (India) Pvt. Ltd. or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice.

Important: These disclosures and disclaimers must be read in conjunction with the research report of which it forms part. Receipt and use of the research report is subject to all aspects of these disclosures and disclaimers. Additional information about the issuers and securities discussed in this research report is available on request.

Certifications: The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known conflict of interest and no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

#### Additional Disclosures of Interest:

Unless specifically mentioned in Point No. 9 below:

- 1. The Research Analyst(s), PCIL, or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. The Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively do not hold more than 1% of the securities of the company (ies)covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. The Research Analyst, his/her associate, his/her relative, and PCIL, do not have any other material conflict of interest at the time of publication of this research report.
- 4. The Research Analyst, PCIL, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 5. The Research Analyst, PCIL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- 6. PCIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 7. The Research Analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 8. The Research Analyst and PCIL has not been engaged in market making activity for the company(ies) covered in the Research report.
- 9. Details of PCIL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr. no.	Particulars	Yes/No
1	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by PCIL	No
2	Whether Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of	No
	the company(ies) covered in the Research report	
3	Whether compensation has been received by PCIL or its associates from the company(ies) covered in the Research report	No
4	PCIL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the	No
	company(ies) covered in the Research report	
5	Research Analyst, his associate, PCIL or its associates have received compensation for investment banking or merchant banking or	No
	brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve	
	months	

Independence: PhillipCapital (India) Pvt. Ltd. has not had an investment banking relationship with, and has not received any compensation for investment banking services from, the subject issuers in the past twelve (12) months, and PhillipCapital (India) Pvt. Ltd does not anticipate receiving or intend to seek compensation for investment banking services from the subject issuers in the next three (3) months. PhillipCapital (India) Pvt. Ltd is not a market maker in the securities mentioned in this research report, although it, or its affiliates/employees, may have positions in, purchase or sell, or be materially interested in any of the securities covered in the report.

Suitability and Risks: This research report is for informational purposes only and is not tailored to the specific investment objectives, financial situation or particular requirements of any individual recipient hereof. Certain securities may give rise to substantial risks and may not be suitable for certain investors. Each investor must make its own determination as to the appropriateness of any securities referred to in this research report based upon the legal, tax and accounting considerations applicable to such investor and its own investment objectives or strategy, its financial situation and its investing experience. The value of any security may be positively or adversely affected by changes in foreign exchange or interest rates, as well as by other financial, economic, or political factors. Past performance is not necessarily indicative of future performance or results.

Sources, Completeness and Accuracy: The material herein is based upon information obtained from sources that PCIPL and the research analyst believe to be reliable, but neither PCIPL nor the research analyst represents or guarantees that the information contained herein is accurate or complete and it should not be relied upon as such. Opinions expressed herein are current opinions as of the date appearing on this material, and are subject to change without notice. Furthermore, PCIPL is under no obligation to update or keep the information current. Without limiting any of the foregoing, in no event shall PCIL, any of its affiliates/employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this document.

Copyright: The copyright in this research report belongs exclusively to PCIPL. All rights are reserved. Any unauthorised use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the PCIPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

Caution: Risk of loss in trading/investment can be substantial and even more than the amount / margin given by you. Investment in securities market are subject to market risks, you are requested to read all the related documents carefully before investing. You should carefully consider whether trading/investment is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. PhillipCapital and any of its employees, directors, associates, group entities, or affiliates shall not be liable for losses, if any, incurred by you. You are further cautioned that trading/investments in financial markets are subject to market risks and are advised to seek independent third party trading/investment advice outside PhillipCapital/group/associates/affiliates/directors/employees before and during your trading/investment. There is no guarantee/assurance as to returns or profits or capital protection or appreciation. PhillipCapital and any of its employees, directors, associates, and/or employees, directors, associates of PhillipCapital's group entities or affiliates is not inducing you for trading/investing in the financial market(s). Trading/Investment decision is your sole responsibility. You must also read the Risk Disclosure Document and Do's and Don'ts before investing.

## **AXIS BANK QUARTERLY UPDATE**

Kindly note that past performance is not necessarily a guide to future performance.

For Detailed Disclaimer: Please visit our website www.phillipcapital.in

#### **IMPORTANT DISCLOSURES FOR U.S. PERSONS**

This research report is a product of PhillipCapital (India) Pvt. Ltd. which is the employer of the research analyst(s) who has prepared the research report. PhillipCapital (India) Pvt Ltd. is authorized to engage in securities activities in India. PHILLIPCAP is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not a Major Institutional Investor.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 40 Wall Street 59th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through PHILLIPCAP. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

#### **Ownership and Material Conflicts of Interest**

Rosenblatt Securities Inc. or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication

#### **Compensation and Investment Banking Activities**

Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

#### **Additional Disclosures**

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither PHILLIPCAP nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

PHILLIPCAP may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of PHILLIPCAP.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by PHILLIPCAP with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of PHILLIPCAP and PHILLIPCAP accepts no liability whatsoever for the actions of third parties in this respect.

## PhillipCapital (India) Pvt. Ltd.

Registered office: 18th floor, Urmi Estate, Ganpatrao Kadam Marg, Lower Parel (West), Mumbai – 400013, India.